insights_auto
Why is 4528 up 3.88%?
Dive Deeperchevron_right
4528:TYO
Ono Pharmaceutical Co Ltd
Â¥2,353.50
arrow_upward
+3.88%(+88.00) 1D
Oct 15, 3:30:00 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4528...
Open
Â¥2,310
High
Â¥2,354
Low
Â¥2,290
Mkt. cap
1.17T
Avg. vol.
1.43M
Volume
1.66M
Dividend
3.40%
Quarterly dividend
Â¥20
Ex-dividend date
Sep 29, 2026
P/E ratio
14.51
52-wk high
Â¥2,674
52-wk low
Â¥1,764
EPS
Â¥162
Shares outstanding
514.12M
No. of employees
4K
Open
Â¥2,310
High
Â¥2,354
Low
Â¥2,290
Mkt. cap
1.17T
Avg. vol.
1.43M
Volume
1.66M
Dividend
3.40%
Quarterly dividend
Â¥20
Ex-dividend date
Sep 29, 2026
P/E ratio
14.51
52-wk high
Â¥2,674
52-wk low
Â¥1,764
EPS
Â¥162
Shares outstanding
514.12M
No. of employees
4K
News stories
From web sources and news partners
Simply Wall Street
·
8 minutes ago
Super Micro Computer (SMCI) Deepens AI Push With OCP Expansion And New Inference Tie Up
The Seattle Times
·
58 minutes ago
Wall Street steadies following jarring drops for AI stocks worldwide
CryptoTicker
·
22 minutes ago
Animoca Brands: Nasdaq listing on hold, Moca Chain live
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical Co Ltd
CEOGyo Sagara | Gyo Sagara
Employees4.21K
Founded1717
HeadquartersOsaka, Osaka, Japan
SectorPharmaceutical industry
Websiteono-pharma.com